DRUG UTILISATION PATTERNS, PREVALENCE OF RISK FACTORS, OPPORTUNISTIC INFECTIONS AND QUALITY OF LIFE AMONG HIV PATIENTS IN A GOVERNMENT HOSPITAL IN BHIMAVARAM
AbstractObjectives: To assess the risk factors, opportunistic infections (OI’s), prescribing patterns along with ADRs, medication adherence, and quality of life (QoL) among HIV patients. Methods: This is an Ambi-directional cohort study conducted at the Government hospital, Bhimavaram, for 6 months from July 2019 to December 2019, including 201 HIV patients’ data. The data were analyzed using GraphPad Prism 8.3.0. Descriptive statistics & paired t-test were employed to assess risk factors, OIs, prescribing patterns, and QoL, respectively. Results: Out of 201 patients. Heterosexuality (96%) was found to be a predominant risk factor in this study. Between type-1 and type 2 HIV patients, Tenofovir Disoproxil Fumarate/ Lamivudine & Efavirenz (TLE) and Tenofovir Disoproxil Fumarate/ Lamivudine/ Lopinavir/ Ritonavir (TL/ATV/r) were the first-line and second-line therapies respectively in type-1 patients; however, TL/LPV/r was reserved for type 2 individuals. Among 201 patients, 55 patients were reported with 60 ADR’s and the predominant ADR was found to be rashes (36%). Approximately 76% were reported with a history of OI’s, the most prevalent being TB (39%). Almost 94% of individuals were highly adherent to ART with the improvement in QoL after treatment. Conclusion: This study concluded that heterosexuality is the major risk factor and is effectively managed by TLE-based ART. It also reported rashes as the most common ADR and TB as the most prevalent OI. QoL in all domains has been improved after ART with greater adherence.
Article Information
22
1632-1639
655 KB
366
English
IJPSR
Roopa Pravallika Koduri, Akhila Kombathula, Kumar V. S. Nemmani, Jakka Venkata Srinivas and Anil Kumar Sagi *
Department of Pharmacy Practice, Shri Vishnu College of Pharmacy, Bhimavaram, Andhra Pradesh, India.
anilkumar@svcp.edu.in
26 June 2021
06 August 2021
14 August 2021
10.13040/IJPSR.0975-8232.13(4).1632-39
01 April 2022